Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 16/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 16/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 16/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.60 |
| ▸ | PTGIR | P43119 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029408 | 0.90 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7093295 | 0.84 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7087378 | 0.84 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7087335 | 0.79 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7090114 | 0.78 | ERBB2 (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027377 | 0.77 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7033773 | 0.76 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL679239 | 0.76 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11042321 | 0.74 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7027315 | 0.73 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ADRA2A 123/4885ADRA2B 98/4885ADRA2C 42/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | ADRA2A 116/4885ADRA2B 88/4885ADRA2C 38/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | ADRA2A 138/4885ADRA2B 76/4885ADRA2C 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.